Steven Kheloussi, PharmD, MBA, FAMCP

Panelists discuss how removing LDL-C targets in 2013 shifted focus from outcomes to statin use, weakening control efforts.

Panelists discuss how social determinants such as access, income, and literacy drive disparities in LDL-C control.

Panelists discuss how real-world programs like PROMPT-LIPID expose undertreatment patterns and guide care improvement.

Panelists discuss how pharmacy-related delays and limited escalation practices widen LDL-C management gaps.

Panelists discuss how: clinical inertia, patient apathy, and the asymptomatic nature of high cholesterol all contribute to undertreatment and poor outcomes.

Panelists discuss how: LDL-C control remains a national crisis, with many patients not on therapy or failing to reach target levels despite the availability of effective treatments.